BOULDER, Colo.--(BUSINESS WIRE)--
Inscripta, developer of the first scalable platform for benchtop Digital Genome Engineering, today announced the appointment of Ron McGrath as Chief Financial Officer. Mr. McGrath has held leadership and financial roles for more than 25 years in the biotechnology and information technology industries, most recently at Illumina, the leader in DNA sequencing technology.
“Ron has tremendous experience in scaling teams and organizations in the U.S. and internationally, and we believe this will be an invaluable asset as Inscripta moves forward on the path to commercialization of our genome engineering platform,” said Kevin Ness, CEO of Inscripta. “His track record of success is impressive, and I am delighted to welcome him to the company and look forward to his expert advice and input as we prepare to launch our platform later this year.”
Before joining Inscripta, Mr. McGrath held a variety of leadership roles during his 13 years at Illumina, Inc. He served as Vice President of Finance, building international finance, controllership functions, and corporate planning, where he closely partnered with the manufacturing, development, and commercial leadership teams to drive growth and profitability initiatives. He also served as Chief of Staff in Operations, with broad responsibilities spanning resource planning and prioritization, customer and pricing analytics, and gross margin optimization. Before joining Illumina, he held financial leadership roles at Memec, LLC, a designer and distributor of semiconductors, and dj Orthopedics, LLC, a medical device manufacturer, and distributor. Mr. McGrath holds an MBA from Pepperdine University and a bachelor’s degree in Quantitative Economics from the University of California, San Diego.
“I am honored to join Inscripta during this exciting phase of growth, as the company prepares to transform the genome engineering industry,” said Mr. McGrath. “This team and technology are uniquely positioned to drive innovation, and I look forward to helping to build the infrastructure that will deliver value to our customers and shareholders.”
Inscripta is developing the world's first scalable platform for benchtop Digital Genome Engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, reagents, and software, will offer a fully automated workflow that enables multiplexed, trackable editing of cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. For more information, visit www.inscripta.com